Iron deficiency (ID) and iron deficiency anemia (IDA) are highly prevalent worldwide.
Oral iron salts, especially ferrous sulfate, are commonly used for the treatment of iron deficiency (ID).
However, its use is associated with gastrointestinal side effects, thus compromising treatment com pliance. Intravenous iron administration is a more costly and logistically complex alternative and
is not risk-free, as infusion and hypersensitivity reactions may occur. Sucrosomial® iron is an oral
formulation consisting of ferric pyrophosphate conveyed by a phospholipid and sucrester matrix
(sucrosome®). Intestinal Sucrosomial® iron absorption is mediated by enterocytes and M cells,
through the paracellular and transcellular routes, and occurs mostly as intact particles. These phar macokinetic properties of Sucrosomial® iron result in higher iron intestinal absorption and excellent
gastrointestinal tolerance compared to oral iron salts. The evidence derived from clinical studies
supports the use of Sucrosomial® iron as a valid first option for the treatment of ID and IDA, espe cially for subjects who are intolerant or refractory to conventional iron salts. Newer evidence also
demonstrates the effectiveness of Sucrosomial® iron, with a lower cost and fewer side effects, in
certain conditions usually treated with IV iron in current clinical practice
